Screener
Ionis Pharmaceuticals IONS Interest Income
Interest Income at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InvestmentIncomeNet.
The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 5:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000874015-26-000251
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Total operating expenses | 370,242 | 312,233 | 733,756 | 590,705 |
| Income (loss) from operations | (102,293) | 139,816 | (219,714) | (7,045) |
| Other income (expense): | ||||
| Investment income | 20,230 | 24,687 | 45,713 | 49,354 |
| Interest expense | (4,618) | (4,114) | (9,778) | (8,223) |
| Interest expense related to sale of future royalties | (17,506) | (18,648) | (34,843) | (37,470) |
| Gain (loss) on investments, net | (10,182) | (18,312) | 12,401 | (20,476) |
| Other income, net | 987 | 102 | 529 | 569 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Ionis Pharmaceuticals's interest income?
- Ionis Pharmaceuticals (IONS) reported interest income of $20.23M in Q2 2026.
- How has Ionis Pharmaceuticals's interest income changed year-over-year?
- Ionis Pharmaceuticals's interest income decreased by 18.1% year-over-year, from $24.69M to $20.23M.
- What is the long-term trend for Ionis Pharmaceuticals's interest income?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's interest income has grown at a 76.6% compound annual growth rate (CAGR), from $10.06M to $97.77M.
- What does interest income mean?
- Income earned from interest-bearing assets including cash deposits, money market funds, treasury securities, corporate bonds, and customer financing receivables.
Ask your AI about Ionis Pharmaceuticals's interest income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude